{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:20:17Z","timestamp":1780482017019,"version":"3.54.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008680","name":"Mallinckrodt LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008680","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014468","name":"Mallinckrodt Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014468","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.conctc.2023.101211","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T13:00:02Z","timestamp":1696510802000},"page":"101211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5605-8995","authenticated-orcid":false,"given":"Ethan","family":"Weinberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2752-3173","authenticated-orcid":false,"given":"Suditi","family":"Rahematpura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1322-5332","authenticated-orcid":false,"given":"Stevan A.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manhal J.","family":"Izzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Simonetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2153-3194","authenticated-orcid":false,"given":"R. Todd","family":"Frederick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond A.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7853-1542","authenticated-orcid":false,"given":"Jade","family":"Ikahihifo-Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Harte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8801-9775","authenticated-orcid":false,"given":"Grace","family":"Kim-Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Witkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurram","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Fricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4898-7778","authenticated-orcid":false,"given":"K. Rajender","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.conctc.2023.101211_bib1","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.3748\/wjg.v27.i26.3984","article-title":"Acute kidney injury and hepatorenal syndrome in cirrhosis","volume":"27","author":"Gupta","year":"2021","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.conctc.2023.101211_bib2","first-page":"11","article-title":"Hepatorenal syndrome","volume":"28","author":"Ng","year":"2007","journal-title":"Clin. Biochem. Rev."},{"issue":"3","key":"10.1016\/j.conctc.2023.101211_bib3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cld.209","article-title":"Current treatment strategies for hepatorenal syndrome","volume":"2","author":"Sola","year":"2013","journal-title":"Clin. Liver Dis."},{"issue":"9","key":"10.1016\/j.conctc.2023.101211_bib4","first-page":"1310","article-title":"Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis","volume":"56","author":"Salerno","year":"2007","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.conctc.2023.101211_bib5","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jhep.2014.12.029","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites","volume":"62","author":"Angeli","year":"2015","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.conctc.2023.101211_bib6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jhep.2019.07.002","article-title":"News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document","volume":"71","author":"Angeli","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.conctc.2023.101211_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.12703\/r\/10-48","article-title":"Recent advances in the understanding and management of hepatorenal syndrome","volume":"10","author":"Simbrunner","year":"2021","journal-title":"Fac Rev."},{"issue":"2","key":"10.1016\/j.conctc.2023.101211_bib8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ccc.2020.11.011","article-title":"Hepatorenal syndrome","volume":"37","author":"Khemichian","year":"2021","journal-title":"Crit. Care Clin."},{"issue":"8","key":"10.1016\/j.conctc.2023.101211_bib9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMra2215289","article-title":"Acute kidney injury in patients with cirrhosis","volume":"388","author":"Nadim","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.conctc.2023.101211_bib10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial","volume":"62","author":"Cavallin","year":"2015","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.conctc.2023.101211_bib11","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1097\/MEG.0000000000000988","article-title":"Terlipressin is superior to midodrine\/octreotide for hepatorenal syndrome type 1","volume":"29","author":"Kalambokis","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.conctc.2023.101211_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.14309\/ajg.0000000000001595","article-title":"Acute-on-Chronic liver failure clinical guidelines","volume":"117","author":"Bajaj","year":"2022","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.conctc.2023.101211_bib13","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of Ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice guidance by the American association for the study of liver diseases","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.conctc.2023.101211_bib14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.conctc.2023.101211_bib15","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","article-title":"Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide","volume":"29","author":"Angeli","year":"1999","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.conctc.2023.101211_bib16","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s10620-006-9312-0","article-title":"Octreotide\/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome","volume":"52","author":"Esrailian","year":"2007","journal-title":"Dig. Dis. Sci."},{"issue":"7","key":"10.1016\/j.conctc.2023.101211_bib17","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/MCG.0b013e318188947c","article-title":"Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome","volume":"43","author":"Skagen","year":"2009","journal-title":"J. Clin. Gastroenterol."},{"issue":"2","key":"10.1016\/j.conctc.2023.101211_bib18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S2468-1253(16)30157-1","article-title":"Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis","volume":"2","author":"Facciorusso","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.conctc.2023.101211_bib19","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.30208","article-title":"Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure","volume":"71","author":"Arora","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.conctc.2023.101211_bib20","doi-asserted-by":"crossref","first-page":"m2687","DOI":"10.1136\/bmj.m2687","article-title":"Hepatorenal syndrome: pathophysiology, diagnosis, and management","volume":"370","author":"Simonetto","year":"2020","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.conctc.2023.101211_bib21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study","volume":"47","author":"Alessandria","year":"2007","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.conctc.2023.101211_bib22","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response","volume":"103","author":"Sharma","year":"2008","journal-title":"Am. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.conctc.2023.101211_bib23","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","article-title":"Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study","volume":"56","author":"Singh","year":"2012","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.conctc.2023.101211_bib24","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/lt.26106","article-title":"Toward norepinephrine as a first-line treatment for all hospitalized patients with hepatorenal syndrome","volume":"27","author":"Paine","year":"2021","journal-title":"Liver Transplant."},{"issue":"5","key":"10.1016\/j.conctc.2023.101211_bib25","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.conctc.2023.101211_bib26","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.conctc.2023.101211_bib27","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa2008290","article-title":"Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome","volume":"384","author":"Wong","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.conctc.2023.101211_bib28","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.28396","article-title":"Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study","volume":"63","author":"Cavallin","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.conctc.2023.101211_bib29","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/j.ajkd.2021.08.016","article-title":"Terlipressin and the treatment of hepatorenal syndrome: how the CONFIRM trial moves the story forward","volume":"79","author":"Belcher","year":"2022","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.conctc.2023.101211_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78044-4","article-title":"An investigation of reconstituted terlipressin infusion stability for use in hepatorenal syndrome","volume":"10","author":"Bui","year":"2020","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.conctc.2023.101211_bib31","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/apt.17195","article-title":"Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure","volume":"56","author":"Wong","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.conctc.2023.101211_bib32","doi-asserted-by":"crossref","DOI":"10.1097\/01.HC9.0000897228.91307.0c","article-title":"Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies","volume":"7","author":"Curry","year":"2023","journal-title":"Hepatol. Commun."},{"issue":"5","key":"10.1016\/j.conctc.2023.101211_bib33","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study","volume":"134","author":"Martin-Llahi","year":"2008","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.conctc.2023.101211_bib34","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0168-8278(97)80428-X","article-title":"Time profile of the haemodynamic effects of terlipressin in portal hypertension","volume":"26","author":"Escorsell","year":"1997","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.conctc.2023.101211_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jhepr.2019.05.002","article-title":"Continuous terlipressin infusion is associated with improved diet intake and muscle strength in patients awaiting liver transplant","volume":"1","author":"Chapman","year":"2019","journal-title":"JHEP Rep."},{"issue":"6","key":"10.1016\/j.conctc.2023.101211_bib36","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1002\/hep.28647","article-title":"Terlipressin given by continuous intravenous infusion or by intravenous boluses: is there already an answer? Letter to the Editor","volume":"64","author":"de Mattos","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.conctc.2023.101211_bib37","first-page":"1179","article-title":"Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology","volume":"137","author":"Gerbes","year":"2009","journal-title":"Sep"},{"issue":"2","key":"10.1016\/j.conctc.2023.101211_bib38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MEG.0000000000001950","article-title":"Safety and efficacy of outpatient continuous terlipressin infusion for the treatment of portal hypertensive complications in cirrhosis","volume":"34","author":"Gow","year":"2022","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.conctc.2023.101211_bib39","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/hep.28325","article-title":"Efficacy of outpatient continuous terlipressin infusions for hepatorenal syndrome","volume":"64","author":"Vasudevan","year":"2016","journal-title":"Hepatology"},{"issue":"S2","key":"10.1016\/j.conctc.2023.101211_bib40","first-page":"118","article-title":"Safety and efficacy of outpatient continuous terlipressin infusions in a liver transplant population. Meeting Abstract","volume":"31","author":"Thwaites","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.conctc.2023.101211_bib41","first-page":"378A","article-title":"Terlipressin given as continuous intravenous infusion is the more suitable schedule for the treatment of type 1 hepatorenal syndrome (HRS) in patients with cirrhosis: results of a controlled clinical study. Meeting abstract","volume":"48","author":"Angeli","year":"2008","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.conctc.2023.101211_bib42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/liv.14866","article-title":"End-stage liver disease: management of hepatorenal syndrome","volume":"41","author":"Mauro","year":"2021","journal-title":"Liver Int."},{"issue":"S1","key":"10.1016\/j.conctc.2023.101211_bib43","first-page":"S145","article-title":"Pretransplant terlipressin treatment for hepatorenal syndrome decreases the need for renal replacement therapy both pre- and posttransplant: a 12-month follow-up analysis of the CONFIRM trial. Meeting abstract","volume":"76","author":"Weinberg","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.conctc.2023.101211_bib44","article-title":"The effect of terlipressin on renal replacement therapy in patients with hepatorenal syndrome","volume":"360","author":"Velez","year":"2023","journal-title":"Kidney"},{"issue":"5","key":"10.1016\/j.conctc.2023.101211_bib45","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/hep.31529","article-title":"Response to terlipressin and albumin is associated with improved liver transplant outcomes in patients with hepatorenal syndrome","volume":"73","author":"Piano","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.conctc.2023.101211_bib46","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jhep.2011.02.002","article-title":"Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?","volume":"55","author":"Piano","year":"2011","journal-title":"J. Hepatol."}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865423001576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865423001576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:10:23Z","timestamp":1762521023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865423001576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":46,"alternative-id":["S2451865423001576"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2023.101211","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2023.101211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101211"}}